NCT00933608 - Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions

Alzheimer's Disease

Interventions

DRUG

memantine

participants will be asked to take memantine (20mg/day) for 16 weeks

DRUG

Placebo

participants will be asked to take 2 tablets per day to match active drug

Trial Locations (1)

NYU School of Medicine, Dept. of Psychiatry, Center for Brain Health, New York